Combining two diabetes drugs with an automated insulin pump
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests if adding semaglutide and empagliflozin to your automated insulin delivery system (like a smart pump) can improve blood sugar control for adults with type 1 diabetes. It may help with both glucose levels and weight management.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had type 1 diabetes for at least one year.
- You have been using an automated insulin delivery (AID) system for at least three months.
- Your body mass index (BMI) is 23 or higher.
- You have not used a GLP-1 receptor agonist (like Ozempic) in the last month or an SGLT2 inhibitor (like Jardiance) in the last two weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a weekly semaglutide injection (a GLP-1 drug) to a closed-loop insulin system can help reduce the need for carb counting in people with type 1 diabetes. It aims to improve blood sugar control and make diabetes management easier.
This study tests if starting two newer diabetes drugs (empagliflozin and semaglutide) soon after diagnosis, along with metformin, helps control blood sugar better than metformin alone. It's for people diagnosed with type 2 diabetes in the last two years who are already taking a high dose of metformin.
This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.
This study tests whether semaglutide, a medicine that helps control blood sugar and reduce weight, can benefit adults with type 1 diabetes who are overweight. If you qualify, you may receive the drug or a placebo, and the study team will monitor your health closely.
This study tests whether adding a new medicine, CS0159, to a standard diabetes drug (semaglutide) can improve liver health and blood sugar in people with fatty liver disease, obesity, and type 2 diabetes. It may help reduce liver fat and support weight loss.
This trial tests a medication (called a GLP-1 receptor agonist) to see if it can help people in the earliest stage of type 1 diabetes keep their insulin-making cells working longer. It might help delay the need for insulin injections.
Hear when a new Diabetes Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.